Clinical trial
Docetaxel in Hormone Refractory Prostate Cancer (HRPC)[Weekly or 3weekly TAX +…
NCT00268710 · Sanofi, Industry · Completed
Key facts
| NCT number | NCT00268710 |
|---|---|
| Title | Docetaxel in Hormone Refractory Prostate Cancer (HRPC)[Weekly or 3weekly TAX + Prednisone in HRPC] |
| Official title | Multicenter Phase II Study of Taxotere (Docetaxel) Administered Weekly or Every Three Weeks in Combination With Prednisone as Second Line Chemotherapy in Patients With Hormone Refractory Prostate Cancer (HRPC) |
| Lead sponsor | Sanofi, Industry |
| Collaborators | Canadian Urologic Oncology Group |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Prostatic Neoplasms |
| Intervention type | Drug |
| Interventions | docetaxel |
| Start date | Feb 1, 2004 |
| Primary completion | Mar 1, 2006 |
| Completion | Mar 1, 2006 |
| First posted | Dec 22, 2005 |
| Last update posted | Dec 7, 2009 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: